Supplementary Figure 2

Studies	Estimate	(95% C.I.)	Ev/Trt
Bloch et.al	0.529	(0.292, 0.767)	9/17
Ylitalo et.al (Arm 1)	0.508	(0.386, 0.629)	33/65
Leonard et.al	0.625	(0.290, 0.960)	5/8
Subgroup Voice therapy (I^2=0 % , P=0.811)	**0.523**	**(0.420, 0.626)**	**47/90**
Ylitalo et.al (Arm 2)	0.346	(0.163, 0.529)	9/26
Carroll et.al (Arm 2)	0.769	(0.540, 0.998)	10/13
Subgroup Surgical excision and Voice therapy (I^2=87.51 % , P=0.005)	**0.552**	**(0.137, 0.966)**	**19/39**
Carroll et.al (Arm 1)	0.714	(0.521, 0.908)	15/21
Subgroup (PPI & another type of Antireflux) with Voice therapy (I^2=NA , P=NA)	**0.714**	**(0.521, 0.908)**	**15/21**
Chang et.al	0.417	(0.256, 0.578)	15/36
Chen et.al	0.389	(0.164, 0.614)	7/18
Ding et.al	0.375	(0.269, 0.481)	30/80
Havas et.al (Arm 1)	0.500	(0.255, 0.745)	8/16
Kobayashi et.al (Arm 1)	0.250	(-0.174, 0.674)	1/4
Dominguez et.al	0.731	(0.560, 0.901)	19/26
Song et.al (Arm 1)	0.167	(-0.132, 0.465)	1/6
Subgroup Surgical excision (I^2=64.93 % , P=0.009)	**0.431**	**(0.302, 0.560)**	**81/186**
Chang et.al	0.512	(0.405, 0.619)	43/84
Chen et.al	0.721	(0.587, 0.855)	31/43
Havas et.al (Arm 2)	0.897	(0.802, 0.993)	35/39
Kobayashi et.al (Arm 2)	0.897	(0.802, 0.993)	35/39
Wani et.al	0.778	(0.586, 0.970)	14/18
Tsunoda et.al	0.917	(0.696, 1.138)	5/5
Subgroup PPI and Voice therapy (I^2=86.85 % , P=0.000)	**0.783**	**(0.640, 0.926)**	**163/228**
Hu et.al	0.778	(0.506, 1.049)	7/9
Subgroup Autologous fat injection and (Antireflux & Voice Therapy) (I^2=NA , P=NA)	**0.778**	**(0.506, 1.049)**	**7/9**
Song et.al (Arm 2)	0.969	(0.883, 1.054)	15/15
Subgroup Surgical excision and Radiotherapy (I^2=NA , P=NA)	**0.969**	**(0.883, 1.054)**	**15/15**
Fink et.al	0.625	(0.290, 0.960)	5/8
Ho et.al	0.875	(0.743, 1.007)	21/24
Hamdan et.al	0.500	(0.154, 0.846)	4/8
Pham et.al	0.833	(0.535, 1.132)	5/6
Subgroup Botulinum toxin and PPI (I^2=42.21 % , P=0.158)	**0.756**	**(0.585, 0.927)**	**35/46**
Ma et.al	0.423	(0.348, 0.497)	71/168
Subgroup Surgical excision and Botulinum toxin and PPI (I^2=NA , P=NA)	**0.423**	**(0.348, 0.497)**	**71/168**
Pan et.al	0.739	(0.560, 0.919)	17/23
Subgroup Botulinum toxin and PPI and steroids (I^2=NA , P=NA)	**0.739**	**(0.560, 0.919)**	**17/23**
Orloff et.al	0.944	(0.795, 1.094)	8/8
Nasri et.al	0.833	(0.535, 1.132)	5/6
Lei et.al (Arm 1)	0.450	(0.232, 0.668)	9/20
Subgroup Botulinum toxin (I^2=85.2 % , P=0.001)	**0.745**	**(0.421, 1.069)**	**22/34**
Lei et.al (Arm 2)	0.962	(0.888, 1.035)	25/26
Subgroup PPI and Mosapride citrate (I^2=NA , P=NA)	**0.962**	**(0.888, 1.035)**	**25/26**
Hillel et.al	0.702	(0.583, 0.821)	40/57
Woo et.al	0.469	(0.296, 0.642)	15/32
Ogawa et.al	0.823	(0.727, 0.918)	51/62
Subgroup PPI and steroids (I^2=84.16 % , P=0.002)	**0.677**	**(0.495, 0.859)**	**106/151**
Roh et.al	0.850	(0.694, 1.006)	17/20
Zhang et.al	0.714	(0.478, 0.951)	10/14
Wang et.al	0.600	(0.296, 0.904)	6/10
Subgroup Steroids (I^2=17.04 % , P=0.300)	**0.766**	**(0.629, 0.903)**	**33/44**
Roh et.al	0.786	(0.571, 1.001)	11/14
Subgroup Voice therapy, antacids, and Anti-inflammatory (I^2=NA , P=NA)	**0.786**	**(0.571, 1.001)**	**11/14**
Marshak et.al	0.917	(0.696, 1.138)	5/5
Sun et.al	0.971	(0.890, 1.051)	16/16
Subgroup Zinc sulfate (I^2=0 % , P=0.653)	**0.964**	**(0.889, 1.040)**	**21/21**
Overall (I^2=89.52 % , P=0.000)	**0.681**	**(0.608, 0.755)**	**688/1115**